Benchmark (BMK) Share Forecast, Price & News

Benchmark (LON:BMK) Frequently Asked Questions

Is Benchmark a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Benchmark in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Benchmark stock.
View analyst ratings for Benchmark or view top-rated stocks.

When is Benchmark's next earnings date?

Benchmark is scheduled to release its next quarterly earnings announcement on Wednesday, May 18th 2022.
View our earnings forecast for Benchmark.

What price target have analysts set for BMK?

1 brokerages have issued 12-month price objectives for Benchmark's stock. Their forecasts range from GBX 80 to GBX 80. On average, they anticipate Benchmark's share price to reach GBX 80 in the next twelve months. This suggests a possible upside of 81.8% from the stock's current price.
View analysts' price targets for Benchmark or view top-rated stocks among Wall Street analysts.

Who are Benchmark's key executives?

Benchmark's management team includes the following people:

• Mr. Trond Williksen, CEO & Director (Age 59, Pay $817.52k)
• Ms. Septima Maguire, CFO & Director
• Ms. Ruth Layton, Co-Founder & Head of Benchmark Sustainability Science
• Mr. Neil Robertson, Head of Operations
• Ms. Ivonne Maria Gloria Cantu, Director of Investor Relations & Corp. Devel. (Age 53)
• Ms. Jennifer Haddouk, Company Sec. & Group Legal Counsel
• Ms. Corina Holmes, Group Head of People
• Mr. Roland James Bonney, Group Lead of Key Account Management (Age 58)
• Mr. David Babington, Managing Director of Improve International
• Mr. John Marshall, Head of Animal Health

Who are some of Benchmark's key competitors?

Some companies that are related to Benchmark include Hydropothecary (THCX), Aurora Cannabis (ACB), Knight Therapeutics (GUD), OrganiGram (OGI), Amryt Pharma (AMYT), HLS Therapeutics (HLS), Supreme Cannabis (FIRE), ESSA Pharma (EPI), ICC Labs (ICC), Leaf Mobile (LEAF), HEXO (HEXO), Medexus Pharmaceuticals (MDP), BioSyent (RX), Green Organic Dutchman (TGOD) and Delta 9 Cannabis (NINE).
View all of BMK's competitors.

What other stocks do shareholders of Benchmark own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Benchmark investors own include Indivior (INDV), Allena Pharmaceuticals (ALNA), (RED), Ampliphi Biosciences (APHB), Clinigen Group (CLIN), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), American Campus Communities (ACC), AcelRx Pharmaceuticals (ACRX) and Aldeyra Therapeutics (ALDX).

What is Benchmark's stock symbol?

Benchmark trades on the London Stock Exchange (LON) under the ticker symbol "BMK."

How do I buy shares of Benchmark?

Shares of BMK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Benchmark's stock price today?

One share of BMK stock can currently be purchased for approximately GBX 44.

How much money does Benchmark make?

Benchmark has a market capitalization of £309.74 million and generates £136.05 million in revenue each year.

How many employees does Benchmark have?

Benchmark employs 796 workers across the globe.

What is Benchmark's official website?

The official website for Benchmark is www.benchmarkplc.com.

How can I contact Benchmark?

Benchmark's mailing address is Benchmark House, 8 Smithy Wood Drive, SHEFFIELD, S35 1QN, United Kingdom. The company can be reached via phone at +44-114-2409935.